$NAVN

Rosen Law Firm sues Navan over false IPO disclosures regarding sales, marketing expenses. Lead plaintiff deadline April 24, 2026.

Rosen Law Firm files securities class action against Enphase Energy over alleged misstatements on inventory, financials, and federal credit impacts. Deadline: April 20, 2026.

Law firm launches class action against $NAVN over alleged failure to disclose surge in sales and marketing expenses following October 2025 offering.

Securities fraud class actions filed against PayPal, NuScale, Corcept, and Navan. Investors must file lead plaintiff motions by April 20-24, 2026.

Navan faces securities class action over failing to disclose $95M sales expense surge (39% increase) in Q3 2025. Investors with $100K+ losses have until April 24, 2026 to file.

Rosen Law Firm files securities class action against $NAVN, alleging false IPO disclosures about sales expenses. Lead plaintiff deadline set for April 24, 2026.

Law firm Kahn Swick & Foti files class action against $UGXX over failed Phase 3 trial for rare bone disease drug setrusumab. Investors can apply as lead plaintiffs by April 6.

Kahn Swick & Foti, LLC filed class action lawsuits against Navan, Kyndryl, and Ultragenyx for alleged securities disclosure violations. Lead plaintiff applications due April 24, 2026.

Navan faces class action lawsuit alleging October 2025 IPO documents omitted planned 39% sales-marketing spending increase. Stock down 63% from $25 IPO price to $9.20.

Robbins LLP filed securities class action against $NAVN, alleging the company concealed a 39% spike in sales and marketing expenses during its October 2025 IPO.

Class action lawsuits filed against Lakeland Industries and Navan Inc. allege misleading disclosures. Lead plaintiff deadline is April 24, 2026.

Navan IPO investors with losses over $100,000 have until April 24, 2026 to file for lead plaintiff status in a class action alleging the company concealed marketing expense increases before going public.

Class action lawsuit filed against Navan for allegedly omitting material information about surging marketing costs in October 2025 IPO documents.

Shareholders sue Zynex for allegedly inflating revenue through improper recognition practices, false insurance claims, and overbilling customers, causing material losses.

Navan faces securities fraud lawsuit over IPO disclosure gaps regarding undisclosed sales expenses and slowing revenue growth. Stock fell 48% since offering.

Class action lawsuit filed against Navan alleging IPO disclosure failures on sales and marketing costs. Stock fell 64% from $25 to $9.01 since offering.

Navan faces class action lawsuit over alleged IPO disclosure failures regarding undisclosed marketing spending plans. Stock plunged 63% after December earnings announcement revealed 39% expense increase.

a16z invests $465M in Navan, making it the fund's second-largest holding. The corporate spending platform has evolved beyond travel booking to offer integrated expense management and AI-powered payment solutions.

Law firm investigates Beta Bionics for potential securities fraud after stock plunged 37% due to slowing patient growth, missing investor expectations on guidance accuracy.